Lu Chen

Prof. Lu Chen


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2018 in Journal of Chemotherapy
Verified
Journal Article
Closed access
MLMengXue Li
MengXue Li
LZLiQin Zhu
LiQin Zhu
Lu ChenLu Chen
Lu Chen
NLNa Li
Na Li
FQFang Qi
Fang Qi
Voriconazole is used to treat fungal infections in patients receiving glucocorticoid therapy in clinic. The objective of this study was to characterize the potential drug–drug interactions (DDIs) between voriconazole and glucocorticoids using physiologically based pharmacokinetic (PBPK) models. Voriconazole and glucocorticoids PBPK models were constructed by using physicochemical data and pharmacokinetic parameters in healthy subjects, and verified by comparing the predicted pharmacokinetic parameters with corresponding data acquired from published literatures. The refined PBPK models were employed to predict the potential DDIs between voriconazole and glucocorticoids. The results showed that the maximum plasma concentration (Cmax) and the area under the plasma concentration-time curve from 0 h to infinity (AUC0→inf) of dexamethasone were increased by 2.44-fold and 2.60-fold when combined with voriconazole, respectively. For methylprednisolone, the Cmax and AUC0→inf were increased by 1.56-fold and 2.23-fold, respectively. Our results indicate that the dose of dexamethasone or methylprednisolone can be reduced to maintain approximately similar exposures when used concomitantly with voriconazole.

14 August 2023 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
CLChao Li
Chao Li
Lu ChenLu Chen
Lu Chen
LLLixian Li
Lixian Li
WCWanyi Chen
Wanyi Chen
Co-administration of Bruton's tyrosine kinase (BTK) inhibitors with nirmatrelvir/ritonavir is challenging because of potential drug-drug interactions (DDIs). However, clinical trials specifically evaluating such DDIs are absent. To evaluate and quantify the DDIs between them and provide rational dose management strategies of BTK inhibitors, we conducted this study using physiologically-based pharmacokinetic (PBPK) models. Physicochemical properties and pharmacokinetic parameters were acquired from the published literature and databases. The PBPK models were developed using Simcyp® software. These models were validated by comparing with published literature values. The successfully validated PBPK models were used to simulate the plasma concentration-time profiles and DDIs in a virtual healthy population receiving BTK inhibitors alone or with ritonavir. Simulated plasma concentration-time profiles and pharmacokinetic parameters of each drug were in agreement with clinically observed values from literatures. Ritonavir increased ibrutinib maximum plasma concentration (Cmax) and the area under plasma concentration-time curve (AUC) 33- and 53.88-fold, respectively, increased zanubrutinib Cmax and AUC 2.57- and 3.18-fold, respectively, and increased acalabrutinib Cmax and AUC 3.85- and 6.54-fold, respectively. Based on our simulations, dose-adjustment strategies may consist of ibrutinib at 25 mg q48h, zanubrutinib at 80 mg twice-daily and acalabrutinib at 25 mg twice-daily with nirmatrelvir/ritonavir. The PBPK models predicted the in vivo pharmacokinetics and the DDIs of BTK inhibitors and ritonavir. The prospective simulations not only provided scientific evidence regarding rational dosing management strategies when initiating nirmatrelvir/ritonavir therapy but also provided a reference for the design of clinical DDIs study that may save resources and time. Paxlovid could increase Cmax and AUC0-τ of BTK inhibitors (ibrutinib, zanubrutinib and acalabrutinib), and dose adjustment strategy of ibrutinib (25 mg q48h), zanubrutinib (80 mg q12h) and acalabrutinib (25 mg q12h) should be considered when combination with nirmatrelvir/ritonavir.

23 March 2021 in IEEE Access
Verified
Journal Article
Open access
ZCZhong Chen
Zhong Chen
JYJun Yan
Jun Yan
Lu ChenLu Chen
Lu Chen
Taking the Steady-state Security Region (SSR) of AC/DC hybrid power system as a link, the mathematical model of coordinated control optimization problem is established by using the complementarity between preventive control and corrective control. Firstly, taking into account the probability and severity of anticipated accidents, a two-layer optimization model of coordinated control with dynamic constraints is established with the lowest total cost of coordinated control as the objective function. Secondly, invalid anticipated accidents are eliminated based on the theory of dominant event, which reduces the scale of the model and the complexity of optimization space. Finally, based on the constraint relaxation outer-layer optimization method, the anticipated accident with the minimum Steady-state Security Distance(SSD) is eliminated from the preventive control subset and incorporated into the corrective control subset, providing fixed anticipated accident subsets for the inner-layer optimization. In the inner-layer optimization, the SSDs are used to replace the power flow equations as the constraint condition, then the nonlinear constraints are transformed into linear constraints, which can reduce the difficulty of solving the mathematical model. The transformed IEEE 39 node AC/DC hybrid system is analyzed and calculated, and the calculation results verify that the proposed method can effectively improve the efficiency of solving optimal control scheme, and provide the possibility for online application.

10 April 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Lu ChenLu Chen
Lu Chen
XWXiaoxiao Wang
Xiaoxiao Wang
LLLixian Li
Lixian Li
YYYi Yang
Yi Yang
YLYao Liu
Yao Liu
WCWanyi Chen
Wanyi Chen
Objectives: The co-administration of Bruton’s tyrosine kinase (BTK) inhibitors with antiretroviral drugs is challenging due to potential drug–drug interactions (DDIs). However, clinical trials specifically assessing such DDIs are lacking. We aimed to evaluate DDIs between the BTK inhibitors ibrutinib, zanubrutinib and acalabrutinib with representative antiretroviral drugs and to provide dose adjustment strategies using physiologically based pharmacokinetic (PBPK) models. Methods: PBPK models were developed in PK-Sim software. Model performance was verified by comparing simulated pharmacokinetic parameters and DDI magnitudes with probe drugs (midazolam or maraviroc) with reported clinical data. The validated models were subsequently applied to assess DDIs and explore dose adjustment strategies. Results: The developed PBPK model accurately describes the pharmacokinetics of each drug. Darunavir/ritonavir substantially increased the maximum plasma concentration (Cmax) of ibrutinib, zanubrutinib, and acalabrutinib by 496%, 312%, and 160%, respectively. In contrast, efavirenz reduced Cmax by 43%, 33%, and 37%, respectively, while etravirine caused smaller decreases of 5%, 0%, and 10%. Based on these predictions, recommended dose adjustment strategies include ibrutinib 105 mg once daily, zanubrutinib 40 mg twice daily, and acalabrutinib 50 mg twice daily when co-administered with darunavir/ritonavir or ibrutinib 980 mg once daily, zanubrutinib 240 mg twice daily, and acalabrutinib 150 mg twice daily when co-administered with efavirenz. No dose adjustment is required with etravirine. Conclusions: The PBPK models accurately predicted the in vivo pharmacokinetics of ibrutinib, zanubrutinib, acalabrutinib, and those of the antiretrovirals darunavir/ritonavir, efavirenz, and etravirine, and the DDIs between them. The dose adjustment strategies provided information valuable to the optimization of antineoplastic therapy in HIV-related lymphoma (HRL) patients.